Zoom inZoom out

IMP: Board Resolution No.36

Imexpharm Corporation announces Board Resolution No.36 dated November 13, 2017 as follows:

Article 1: The Board of Directors approved the report on business performance in the first nine months of 2017:

-          Total revenue in 09 months of 2017: VND763.8 billion, increasing 17.2% compared to the same period of 2016, reaching 60.6% target;

-          Profit before tax in 09 months of 2017: VND111.0 billion, increasing 39.8% compared to the same period of 2016, reaching 69.4% target.

Article 2: The Board of Directors approved the progress of projects as below:

-          Vinh Loc High-Tech Antibiotic Factory: The packages all has been completed 95%. This project was disbursed 75% of the expected budget. The factory is expected to go into operation in late 2018 or early 2019.

-          Binh Duong High-Tech Pharmaceutical Factory: The project has been completed 65% - 70%, disbursed 49% of the expected budget. The factory is expected to go into operation in Quarter I/2020.

Article 3: The Board of Directors approved the business plan for Quarter IV/2017:

-          Total revenue in Quarter IV/2017: VND433.2 billion – VND471.0 billion. Total revenue in 2017: 95% - 98% of the year’s target (VND1,260 billion);

-          Profit before tax in Quarter IV/2017: VND49.0 billion – VND54.0 billion. Total profit before tax and before the distribution to the Fund for Development of Science and Technology: 100% - 103.1% of the year’s target (VND160 billion).

Article 4: The Board of Directors approved the handling of the debts which are eligible for remission with the total amount of VND1,256,808,183.

Article 5: The Board of Directors approved the interim cash dividend payment for 2017 with the ratio of 5% on the charter capital.

Article 6: The Board of Directors approved the business plan for 2018: the growth rate of revenue: 18% - 20%; the growth rate of profit before tax and before the distribution to the Fund for Development of Science and Technology: 16% - 18% compared to 2017.

Article 7: This resolution shall be effect from the date of signing. 

HOSE

 

 

Show email

Enter the number:    =   

  

IMP: Board Resolution No.36

Imexpharm Corporation announces Board Resolution No.36 dated November 13, 2017 as follows:

Article 1: The Board of Directors approved the report on business performance in the first nine months of 2017:

-          Total revenue in 09 months of 2017: VND763.8 billion, increasing 17.2% compared to the same period of 2016, reaching 60.6% target;

-          Profit before tax in 09 months of 2017: VND111.0 billion, increasing 39.8% compared to the same period of 2016, reaching 69.4% target.

Article 2: The Board of Directors approved the progress of projects as below:

-          Vinh Loc High-Tech Antibiotic Factory: The packages all has been completed 95%. This project was disbursed 75% of the expected budget. The factory is expected to go into operation in late 2018 or early 2019.

-          Binh Duong High-Tech Pharmaceutical Factory: The project has been completed 65% - 70%, disbursed 49% of the expected budget. The factory is expected to go into operation in Quarter I/2020.

Article 3: The Board of Directors approved the business plan for Quarter IV/2017:

-          Total revenue in Quarter IV/2017: VND433.2 billion – VND471.0 billion. Total revenue in 2017: 95% - 98% of the year’s target (VND1,260 billion);

-          Profit before tax in Quarter IV/2017: VND49.0 billion – VND54.0 billion. Total profit before tax and before the distribution to the Fund for Development of Science and Technology: 100% - 103.1% of the year’s target (VND160 billion).

Article 4: The Board of Directors approved the handling of the debts which are eligible for remission with the total amount of VND1,256,808,183.

Article 5: The Board of Directors approved the interim cash dividend payment for 2017 with the ratio of 5% on the charter capital.

Article 6: The Board of Directors approved the business plan for 2018: the growth rate of revenue: 18% - 20%; the growth rate of profit before tax and before the distribution to the Fund for Development of Science and Technology: 16% - 18% compared to 2017.

Article 7: This resolution shall be effect from the date of signing. 

HOSE

Symbol Lookup

Close

Close